CVM - Cel-Sci: Fabulous Story Stock Works To Pass Muster With FDA
2024-02-12 01:21:58 ET
Summary
- The company's focus is on its cancer pretreatment therapy, Multikine, which aims to boost the immune response before standard cancer treatments.
- After its long years in development, CVM is anxious for quick regulatory approval.
- CEL-SCI's future is highly risky due to the challenges it has faced in the development of Multikine and its financial struggles.
I am a long-term follower and chronicler of CEL-SCI ( CVM ). My initial CEL-SCI article was 08/2019's CEL-SCI: A Risky Bet. My most recent was 07/2023's "Cel-Sci: Would-Be Cancer Giant Taking Baby Steps"....
Cel-Sci: Fabulous Story Stock Works To Pass Muster With FDA